
16 April 2019

Michelle Childs
Global Head of Policy Advocacy
DNDi’s success is only possible through innovative partnerships

Over 160 partnerships worldwide

CRITERIA FOR SUCCESS
- Share the same vision
- Mutual understanding
- Involvement throughout the whole process

Universities & Research Institutes
PDPs
Int. Org. & NGOs
Biotechs
CROs
Pharmaceutical companies
IP & Access: DNDi vision

Affordable treatment and equitable access to patients in need
- Delinking the costs of R&D from the price of products
- DNDi activities not financed by IP revenues
- No partnership without overcoming IP barriers which could prevent access

Develop drugs as public goods, when possible
- Disseminate the results of DNDi work
- Encourage open publication of research data and technology transfer
- Decisions regarding ownership of patents and licensing terms made on a case-by-case basis
DNDI’s R&D and Access strategies

- **Research (Discovery)**
  - Long-term projects
    - New chemical entities (NCEs)
    - Target Product Profiles: needs, acceptability, safety, quality, end-price
    - Stakeholder involvement and public leadership from the beginning
    - Open, collaborative, drug discovery

- **Translation**
  - Medium-term projects
    - New formulations
    - New indications for existing drugs
    - Licensing terms that reduce bottlenecks, and allow access to knowledge and medicines
    - Multisectoral stakeholder platforms
    - Clinical capacity-building in public and private sector

- **Development**
  - Short-term projects
    - Completing registration dossier
    - Geographical extension
    - Adapted regulatory approaches
    - Enable access and scale-up through working with treatment providers and communities
    - Updated evidence-based guidance
    - Technology transfer

- **Implementation**
  - 1-2 years
  - New formulations
  - New indications for existing drugs
  - Completing registration dossier
  - Geographical extension
  - Adapted regulatory approaches
  - Enable access and scale-up through working with treatment providers and communities
  - Updated evidence-based guidance
  - Technology transfer
Pandemic Response Box (PRB) - MMV and DNDi

- **Concept:** To provide free-to-access first-line screening compounds for use in addressing future pandemic outbreaks
  - Complimentary to the existing toolboxes from MMV (e.g. Pathogen Box, Malaria Box)
  - Collection of known antibacterials, antifungals and antivirals
  - 400 diverse compounds selected based on diversity of target pathogen and mechanism of action
  - Obligation: Screening results publicly available, publish in open access journal
  - Launched Jan 2019 >35 requests for copy of the box to date
NTD Drug Discovery Booster

- Identify new molecule of interest with moderate antiparasitic activity
- Mine proprietary collections of millions of compounds to find “similar” structures
- Feedback results to improve the mining process
- Test compounds for anti-parasitic activity

- Speeds up the process. Cheaper: Est USD 90,000 saving per iteration
- Four hit series approved already
- Opens doors into previously inaccessible «proprietary» chemical space
- Engages cutting edge science and scientists
- Publication of results by DNDi instead of patent filing. Royalty-free licenses granted to DNDi on pre-existing IP for use in NTDs
A pan-genotypic HCV treatment - Wide access licence

- DNDi, Pharco and Presidio agreement to test combination of sofosbuvir + ravidasvir
- Partnership with Malaysia and Thailand to conduct Phase II/III multicentre study
- Using innovative licensing agreement or TRIPS flexibilities
- Ravidasvir licence includes all MICs
Downstream:
8 new treatments delivered since 2007

- **2007 ASAQ**
  - Malaria
  - >500 million patients reached

- **2008 ASMQ**
  - Malaria
  - Used in Africa and Asia

- **2009 NECT**
  - Sleeping sickness
  - 100% of stage-2 patients

- **2010 SSG&PM**
  - Visceral leishmaniasis in E Africa
  - Now 1st line in all countries

- **2011 PAEDIATRIC BENZNIDAZOLE**
  - Chagas disease
  - Two sources developed

- **2011 NEW VL TREATMENT ASIA**
  - Visceral leishmaniasis in Asia
  - Support to disease elimination

- **2016 SUPERBOOSTER THERAPY**
  - Paediatric HIV
  - Recommended by WHO

- **2018 FEXINIDAZOLE**
  - Sleeping sickness
  - Approved by European Medicines Agency, first all-oral treatment
THANK YOU
TO ALL OUR
PARTNERS &
DONORS